Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma

Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis

(2012) Akira Tokumura et al.   International Journal of Medical Sciences

LPA Receptors: Subtypes and Biological Actions

(2010) Ji Woong Choi et al.   Annual Review of Pharmacology and Toxicology

Lysophosphatidic Acid Induces αvβ6 Integrin-Mediated TGF-β Activation via the LPA2 Receptor and the Small G Protein Gαq

(2009) Ming Yan Xu et al.   AMERICAN JOURNAL OF PATHOLOGY

Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin

(2008) Ausra Milano et al.   PLoS One

In perspective: Murine models of scleroderma

(2008) Minghua Wu et al.   Current Rheumatology Reports

Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-β responsiveness

(2007) Yasuji Mori et al.   EXPERIMENTAL CELL RESEARCH